• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by STAAR Surgical Company

    8/5/25 6:33:21 PM ET
    $STAA
    Ophthalmic Goods
    Health Care
    Get the next $STAA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001227308
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    STAAR SURGICAL CO
    SEC File Number
    000-11634
    Address of Issuer
    1911 WALKER AVE
    MONROVIA
    CALIFORNIA
    91016
    Phone
    6263037902
    Name of Person for Whose Account the Securities are To Be Sold
    WEISNER AIMEE S
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Former Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Merrill Lynch
    520 Newport Center Drive
    Floor 20
    Newport Beach � CA � 92660
    13491362523.414952612908/05/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common08/07/2023Open Market PurchaseN/ACheckbox not checked200008/09/2023Cash
    Common06/15/2024Restricted Stock Unit VestSTAAR Surgical CompanyCheckbox not checked341706/15/2024N/A
    Common06/18/2025Restricted Stock Unit VestSTAAR Surgical CompanyCheckbox not checked807406/18/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Sale was processed for the Saeman-Weisner Family Trust, for which Aimee S Weisner is Trustee.
    Date of Notice
    08/05/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Aimee S Weisner

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $STAA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STAA

    DatePrice TargetRatingAnalyst
    4/21/2025$17.00Equal Weight
    Wells Fargo
    2/12/2025Buy → Hold
    Jefferies
    2/12/2025$45.00 → $17.00Outperform → Neutral
    Mizuho
    2/12/2025Buy → Neutral
    BTIG Research
    2/12/2025Outperform → Mkt Perform
    William Blair
    7/15/2024$50.00 → $37.00Equal-Weight → Underweight
    Morgan Stanley
    6/11/2024$46.00Neutral → Buy
    BTIG Research
    3/11/2024$30.00 → $50.00Hold → Buy
    Stifel
    More analyst ratings

    $STAA
    SEC Filings

    View All

    SEC Form 10-Q filed by STAAR Surgical Company

    10-Q - STAAR SURGICAL CO (0000718937) (Filer)

    8/6/25 4:05:55 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    8/6/25 4:02:32 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    8/6/25 8:00:14 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STAAR Surgical Reports Second Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million

    8/6/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Date: Wednesday, August 6, 2025 Time: 4:30 p.m. ET Location: https://registrations.events/direct/IDX8578398 The live webcast, including an option to pre-register, can be accessed at the preceding link o

    7/31/25 10:03:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Broadwood Partners, L.P. bought $2,866,428 worth of shares (187,227 units at $15.31) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/10/25 7:00:22 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $13,627,504 worth of shares (845,220 units at $16.12) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/7/25 8:28:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $941,285 worth of shares (53,969 units at $17.44) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/2/25 8:33:34 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jiang Wei converted options into 20,967 shares, increasing direct ownership by 592% to 24,510 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    8/13/25 6:39:57 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by CFO Andrews Deborah J

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/26/25 6:31:03 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Zhou Lilian Yansheng

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/26/25 6:29:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on STAAR Surgical with a new price target

    Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00

    4/21/25 8:38:55 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by Jefferies

    Jefferies downgraded STAAR Surgical from Buy to Hold

    2/12/25 11:13:24 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by Mizuho with a new price target

    Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously

    2/12/25 7:11:03 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020. "Deborah has blended seamlessly with the leadership team, and we quickly realized that her deep knowledge of STAAR and her skills, abilities, and approach made her the perfect choice to be STAAR's next CFO," said the Company's CEO and Board member, Stephen Farrell. "In the last few months, Deborah has

    6/25/25 9:28:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Leadership Transition

    Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to

    2/26/25 4:45:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

    New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:

    5/1/24 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Financials

    Live finance-specific insights

    View All

    STAAR Surgical Reports Second Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million

    8/6/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Date: Wednesday, August 6, 2025 Time: 4:30 p.m. ET Location: https://registrations.events/direct/IDX8578398 The live webcast, including an option to pre-register, can be accessed at the preceding link o

    7/31/25 10:03:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    1/26/24 9:19:42 AM ET
    $STAA
    Ophthalmic Goods
    Health Care